News & Events about Bellicum Pharmaceuticals Inc.
HOUSTON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced that an abstract on early results from a Phase 1 clinical trial for BPX-601, its lead GoCAR-T product candidate, ...
HOUSTON, Dec. 11, 2022 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced a poster presentation by the University of North Carolina Lineberger Comprehensive Cancer Center (UNC Lineberger...
StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM Get Rating) in a report issued on Monday morning. The firm issued a sell rating on the biopharmaceutical companys stock. Separately, TheStreet downgraded shares of Bellicum Pharmaceuticals from a c- rating to a d- ...
Ticker Report
6 months ago
StockNews.com initiated coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM Get Rating) in a report published on Sunday. The firm issued a sell rating on the biopharmaceutical companys stock. Separately, TheStreet lowered shares of Bellicum Pharmaceuticals from a c- rating to ...
Ticker Report
7 months ago
StockNews.com assumed coverage on shares of Bellicum Pharmaceuticals (NASDAQ:BLCM Get Rating) in a report released on Thursday. The brokerage issued a sell rating on the biopharmaceutical companys stock. Separately, TheStreet lowered Bellicum Pharmaceuticals from a c- rating to a d- ...